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Abstract
Loss of WWOX expression has been reported in many different cancers including breast cancer. Elucidating the function of
this gene in adult tissues has not been possible with full Wwox knockout models. Here we characterize the first conditional
models of Wwox ablation in mouse mammary epithelium utilizing two transgenic lines expressing Cre recombinase, keratin
5-Cre (BK5-Cre) and MMTV-Cre. In the BK5-Cre model we observed very efficient Wwox ablation in KO mammary glands.
However, BK5-Cre Wwox KO animals die prematurely for unknown reasons. In the MMTV-Cre model we observed significant
ablation of Wwox in mammary epithelium with no effect on survival. In both of these models we found that Wwox deletion
resulted in impaired mammary branching morphogenesis. We demonstrate that loss of Wwox is not carcinogenic in our KO
models. Furthermore, no evidence of increase proliferation or development of premalignant lesions was observed. In none
of the models did loss of a single Wwox allele (i.e. haploinsufficiency) have any observable phenotypic effect in mammary
gland. To better understand the function of Wwox in the mammary gland, transcriptome profiling was performed. We
observed that Wwox ablation results in the deregulation of genes involved in various cellular processes. We found that
expression of the non-canonical Wnt ligand, Wnt5a, was significantly upregulated in Wwox KO mammary epithelium.
Interestingly, we also determined that components of the Jak/Stat3 signaling pathway were upregulated in KO mice and
this correlated with a very robust increase in phospho-Stat3 signaling, which warrants further testing. Even though the loss
of Wwox expression in breast and other cancers is very well documented, our findings suggest that Wwox does not act as a
classical tumor suppressor as previously thought.
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Introduction
The WW domain-containing oxidoreductase (WWOX) gene was
identified as a potential tumor suppressor gene mapping to
chromosomal region 16q23 [1,2]. The WWOX gene spans
.1.1 Mb and overlaps the FRA16D common chromosomal fragile
site [1,2,3]. Disruptions of the WWOX locus by hemi, homozygous
deletions and other rearrangements have been reported in various
human malignancies including breast, prostate, ovarian, lung, liver
cancer and multiple myeloma [1,4,5]. WWOX is highly conserved
throughout evolution and in mouse the Wwox gene is 93% identical
to its human counterpart. Interestingly the mouse Wwox gene also
co-localizes with the murine chromosomal fragile site Fra8E1 [6].
Significant research has been performed to elucidate the normal
and putative tumor-suppressive roles of WWOX. The WWOX
protein has a molecular mass of 46 kD with two functional motifs
consisting of two N-terminal WW domains and a short-chain
dehydrogenase (SDR) domain [1,7]. The WW domains of WWOX
have been found to be essential for protein-protein interactions
with proteins harboring PPXY motifs [8] and the substrate/s for
the WWOX NADH/NADPH oxidoreductase enzymatic domain
are yet to be identified. Several potential protein partners have
been identified and include regulators of cell growth and apoptosis
as well as various transcription factors [8,9,10,11,12,13]. The
putative role of WWOX as a tumor suppressor has been suggested
by various studies observing suppressed in vivo tumorigenicity of
human cancer cells when WWOX was ectopically overexpressed
[14,15,16,17].
Our group, as well as others, have generated mouse models of
Wwox knockdown to gain a better understanding of the in vivo
functions of Wwox in development and cancer. Aqeilan et al.
generated a full knockout (KO) mouse model via targeted
disruption of the gene. Even though all mice die by 3–4 weeks
these authors reported the development of periostal osteosarcomas
but only in 3 of 11 pups analyzed [18]. Our group generated and
characterized mice harboring a conditional Wwox allele in which
exon 1 was flanked by loxP sites [19]. Upon breeding these mice
with EIIA-Cre transgenic mice, we generated full Wwox KO mice
and observed that these mice displayed severe metabolic defects,
growth retardation and all mice died by 3 weeks of age as
previously observed [19], however in contrast with the findings of
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detected in these short-lived Wwox KO mice [19].
We are interested in understanding the normal and putative
tumor-suppressive functions of WWOX in more detail. Since we
and others observed consistent and significant loss of WWOX
expression in breast cancer [20,21,22,23] we focused first in the
mammary gland. Here we report the characterization of
conditional ablation of Wwox in mouse mammary gland using
two approaches, we utilized transgenic lines with Cre recombinase
under control of a Keratin 5 promoter (BK5-Cre) and also under the
MMTV promoter (MMTV-Cre) in order to inactive Wwox in the
mammary epithelium.
Results
Assessment of two Wwox conditional KO models in
mouse mammary epithelium
To determine the role of Wwox in the murine mammary gland,
Wwox
flox/flox mice were mated with mice carrying a transgene
expressing Cre recombinase resulting in the conditional deletion of
the Wwox gene in mammary epithelium. To this end we tested two
independent models of Cre driven recombination. The first
conditional KO model had Cre recombinase expression driven
by the bovine keratin 5 promoter (BK5-Cre). The BK5 promoter is
activated in utero (E13.5) in epithelial precursor cells [24]. In the
second model, the MMTV promoter drove Cre expression
(MMTV-Cre). The MMTV promoter in the transgenic Line D is
expressed in various tissues and is maximally turned on in
mammary gland epithelium at approximately 22 days of age [25].
To examine Wwox protein expression and the efficacy of Wwox
ablation in each of these models we analyzed histological sections
of mammary glands from female mice stained with Wwox
antibody. We observed high levels of Wwox expression in the
cytoplasm of mammary epithelial cells of 8 week virgin BK5 Wwox
WT control mice and this expression was largely absent in BK5 KO
mice (Figures 1 A and B). This loss of Wwox expression was also
clear in mammary glands from pregnant (P18.5 days) Wwox KO
mice even after the burst of epithelial proliferation associated with
pregnancy (Figures 1 C and D). In the MMTV-Cre model we found
that Wwox ablation was very effective as well (Figures 1 E and F).
We observed however isolated patches of epithelial structures
expressing Wwox indicative of some mosaicism but only in some
mice. This heterogeneity in the MMTV Cre model is not
uncommon with Cre systems and is likely due to the mosaic
nature of Cre expression and perhaps incomplete recombination
affecting some cells in some mice. However, this mosaicism does
not result in repopulation of the mammary gland by Wwox-
positive epithelium as discussed in a follow up section.
We further analyzed the extent of Wwox deletion in the BK5-Cre
model at the RNA level by real-time PCR. We observed that Wwox
expression was dramatically decreased in both 8 week virgin and
P18.5 Wwox KO mammary epithelial organoids when compared to
their WT counterparts (Figure 2). These results demonstrate that
WwoxdeletionbyuseoftheBK5-CreandMMTV-Cretransgeniclines
is very effective in mouse mammary epithelium.
Long-term follow up experiments BK5-Cre model
In order to determine the effects of long-term Wwox ablation in
the mammary gland and to test whether lack of Wwox expression
was tumorigenic we set up standard survival experiments. BK5-
Cre
+; Wwox
flox/flox males and females survived weaning, were fertile
and females were able to lactate. However, inexplicably, BK5 KO
mice died prematurely at an early age. The youngest animal died
at 68 days of age and no BK5 KO mouse survived longer that 117
days of age (0% survival, n=22). This premature death was
independent of gender as 9 females and 13 males were included in
the study. BK5-Cre
(2); Wwox
flox/flox (WT), mice exhibited 100%
survival over the same observation period. It is also important to
note that loss of one Wwox allele in the BK5-Cre
(+); Wwox
+/flox
heterozygous mice had no effect on survival (100% survival,
n=41, Figure S1). Numerous groups of experimental animals
were generated independent of the described survival study with
the same results. We performed comprehensive histopathological,
hematological and blood chemistry analyses on these BK5-Cre
Wwox KO mice before dead and could not determine a reason for
the relatively sudden deaths.
WeobservednotumorformationinanyoftheBK5KOmammary
glands during their relatively short lifespan (mean=115 days).
Importantly, none of the BK5-Cre
(+); Wwox
+/flox heterozygous mice
develop tumors even after over a year of follow up, indicating that
lack of one Wwox allele (i.e. equivalent to haploinsufficiency) is not
tumorigenic in the mouse mammary gland.
Since Keratin 5 is highly expressed in cells of the basal layer of
multiple epithelia including the skin, we carefully inspected the
epidermis of BK5 KO mice. We confirmed lack of Wwox
expression in epidermis of BK5 KO mice by means of immuno-
histochemistry (data not shown). We observed no obvious macro
or microscopic abnormal skin phenotype. Furthermore, BK5 KO
mice displayed the normal bilayer architecture of mouse skin with
Figure 1. Conditional KO of Wwox via BK5-Cre and MMTV-Cre. (A–
F) Immunostaining of formalin-fixed histological sections of mammary
glands from each model of deletion reveals strong cytoplasmic Wwox
staining in WT samples and significant loss of Wwox protein expression
in KO animals. (A) 8 week virgin BK5 Wwox WT, (B) 8 week virgin BK5
Wwox KO, (C) P18.5 days BK5 Wwox WT, (D) P18.5 days BK5 Wwox KO, (E)
24 week virgin MMTV Wwox WT, (F) 24 week MMTV Wwox KO. Rabbit
anti-Wwox [14] antibody was used at a 1:50 dilution and counterstained
with hematoxylin. All images were obtained at the same 106
magnification.
doi:10.1371/journal.pone.0036618.g001
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premalignant or tumorigenic lesions spontaneously developed in
either BK5 KO or heterozygous mice.
Histopathological evaluation of mammary gland tissue sections
from multiple BK5 KO and Wwox
+/flox mice at various stages of
development, revealed no signs of malignancy or premalignant
changes. As can be observed in Figure 1 B no evidence of
hyperplasia is noted. Similarly, no evidence of malignancy or
hyperplastic nodules were observed in any of the whole mount
preparations obtained from BK5 KO mice.
Keratin 5 immunostaining on BK5 KO mammary gland
revealed no obvious abnormalities in differentiation (Figure S2).
We also analyzed the effect of Wwox ablation on proliferation in
the mammary gland via immunohistochemical staining for Ki-67
and found no statistical difference between WT and KO mice in
the BK5-Cre model (data not shown). Importantly, we also found
no difference in ERa or PR expression between the BK5 Wwox
WT and KO groups as determined by immunohistochemical
staining on mammary gland tissue sections from 8 week and 12
week virgin female mice (data not shown).
In order to extend the observation period to monitor the effects
of Wwox ablation in mammary epithelium of the BK5 KO model,
we performed transplantation experiments of mammary epitheli-
um from 12 week old BK5 KO mice into the cleared mammary fat
pads of 4–5 week old virgin SCID female mice (n=10). We
followed the SCID recipient mice for 9 additional months and did
not observe tumor formation in any of the recipient mice. At the
end of the observation period transplanted mammary fat pads
were dissected and prepared for whole mounts. The obtained
mammary pad whole mounts were evaluated after carmine alum
staining confirming the successful grafting of the donor epithelium
in 100% of the cases. We did not observe the development of any
premalignant or malignant lesions in these whole mount
preparations (data not shown).
Long-term follow up experiments MMTV-Cre model
The MMTV-Cre line D expresses the Cre recombinase in
luminal and myoepithelial cells of the mammary gland and is
significantly expressed at approximately 22 days of age [25]. In
contrast with the BK5-Cre KO model, we observed that Wwox
deletion by means of the MMTV-Cre system had no effect in
survival and natural aging. We followed 60 MMTV-Cre(+);
Wwox
flox/flox, i.e. KO mice (30 females, 30 males) and 23 MMTV-
Cre(2); Wwox
flox/flox, i.e. WT mice (13 females, 10 males) for up to
1.4 years and observed no statistical difference in survival between
the two groups. Importantly, and like with the BK5-Cre model,
when whole mounts or histological sections of mammary glands
were analyzed we found no evidence of hyperplasia, premalignant
or malignant lesions (Figure 1F). We also observed no evidence of
tumor formation in any other tissue known to be affected by
MMTV-Cre such as the salivary gland [25].
Given the moderate to mild mosaicism in Wwox expression
detected in some MMTV-Cre KO mice, we investigated whether
Wwox-positive epithelial cells could gain an advantage over the
Wwox-negative epithelium and repopulate the mammary gland
later in life. To this end we analyzed Wwox expression in the
mammary glands of WT (n=8) and KO (n=17) mice when they
reached1.4yearsofageattheendofthesurvivalstudy.Wefoundas
expected that all Wwox WT mammary glands were still strongly
positive for Wwox expression and we observed that over half of the
Wwox KO glands were completely negative (n=9) for Wwox
expression indicating effective deletion of Wwox while the
remaining samples (n=8) showed some mosaicism with areas
displaying some epithelial structures positive and other negative for
Wwox expression, indicating that even though the mosaicism
remained the Wwox expressing cells do not overtake the mammary
gland.
Wwox deletion results in aberrant mammary branching
morphogenesis
By simple microscopic inspection of the mammary whole
mounts obtained from the BK5 Wwox KO and MMTV Wwox KO
mice we observed a significant impairment in branching
development when comparing with the WT counterparts. In
some cases the impairment in mammary fat pad ductal invasion
and expansion was very dramatic and extreme developing just a
rudimentary mammary epithelium or just a few ductal structures
with little or no branching (Figures 3 A–C).
In order to quantitate these observations we performed
morphometric determinations of mammary branching. To this
end whole mounts of the 4
th inguinal mammary glands were
collected from virgin female mice at 12 weeks of age from BK5
Cre(2) WT, BK5 Cre(+)W Tand BK5 KO. We observed some
impairment in branching morphogenesis in the control glands
expressing Cre recombinase when compared with the Cre
negative counterparts. However we observed a statistical signifi-
cant decrease in branching in the mammary glands from the BK5
Wwox KO mice when compared with either of the controls
(Figures 3 A, B, and D).
Importantly, the impaired branching observed in the BK5 KO
mammary gland did not impede the mammary epithelium to
reach functional maturity and differentiation during pregnancy.
Furthermore, BK5 Wwox KO mice were able to lactate and
expressed similar levels of the differentiation markers Wap and b-
casein as determined by qRT-PCR (data not shown).
In the MMTV-Cre model of Wwox deletion we also observed a
similar phenomenon in reduced branching (Figure 3C). However
such phenotype was more heterogeneous than with the BK5-Cre
model. The branching phenotype in MMTV Wwox KO mice
Figure 2. Wwox mRNA expression in BK5-Cre model of Wwox
deletion. qRT-PCR was used to determine the mRNA expression of
Wwox in mammary epithelial organoids from BK5 Wwox WT and KO
animals. The box plots show dramatically decreased Wwox mRNA levels
in epithelium from 8 week virgin (A) and P18.5 days (B) Wwox KO
mammary epithelium when compared to their respective WT counter-
parts. Mammary epithelial organoids were isolated from 3 different WT
and 3 different KO mice in each group. Samples from each mouse were
run individually in triplicate to assess Wwox expression. Samples were
normalized to 18S expression.
doi:10.1371/journal.pone.0036618.g002
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We did not detect statistically significant differences at 12 weeks of
age given the large standard deviations observed in MMTV Wwox
KO mice (data not shown). However, analyses from older MMTV-
Cre females (24 weeks of age) detected significant differences in
branching (6.8+/20.32 vs. 3.8+/21.33 branches/mm, p=0.017,
Figures 3 C and E).
Global gene expression changes in Wwox ablated
mammary epithelium
To determine the effect of Wwox ablation on global gene
expression in mammary epithelium we performed gene expression
microarray analyses on RNA obtained from 8 week old BK5 Wwox
KO and WT mammary epithelium (n=3 WT mice and 3 KO
mice). We decided to pursue these studies with the BK5-Cre model
given the uniformity and efficiency in Wwox ablation. The
statistical analysis of the Affymetrix gene chip expression profiling
data identified 913 probes differentially expressed between Wwox
KO and Wwox WT mammary gland epithelium (p,0.01; 2 fold
changes). Among the 913 probes, 777 were up-modulated and 136
were down-modulated in the mammary gland epithelium derived
from the Wwox KO mice model (Figure 4A and B; Table S1). We
used the DAVID resource for automated annotation and
enrichment analysis of the differentially expressed genes based
on GO database. In addition, we employed REVIGO resource for
summarization and visualization of the significant GO term
semantic similarities (p,0.025). Among the statistically significant
over-represented categories under Biological Processes, we found
the Wnt signaling pathway, skeletal system development/bone
morphogenesis, and tissue remodeling related genes (Figure 4 C).
In addition, categories of genes found in cell migration and
adhesion were also highly enriched related genes in the Wwox-KO
mammary gland expression profile.
Validation of gene expression changes
One of the most significantly upregulated genes in Wwox-KO
mammary epithelium was the non-canonical Wnt pathway ligand
Wnt5a (fold change=3.01, p=0.000057). Wnt5a is expressed
during all stages of mammary gland development except during
lactation [26]. We sought to validate the findings of our
microarray by performing semi-quantitative RT-PCR on RNA
from the mammary gland epithelial organoids of three 8 week old
WT mice compared to three Wwox-KO mice (Figure 5, lanes 1–3
and 7–9). Wnt5a expression was observed to be variable in
unsynchronized mice; mammary epithelial samples from two WT
mice displayed very low levels of Wnt5a expression while one
displayed high Wnt5a expression. We observed that all Wwox-KO
mammary epithelial samples exhibited upregulation of Wnt5a.W e
then tested this expression in the pregnancy synchronized
epithelium of P18.5 mice and found that 2 out of 3 WT mammary
glands displayed low levels of Wnt5a expression while all Wwox-KO
mammary glands tested exhibited increased levels of Wnt5a
mRNA (Figure 5, lanes 4–6 and 10–12).
We then sought to determine possible mechanisms by which
Wnt5a expression could be upregulated in Wwox-KO mammary
gland. IL-6 induced Jak/Stat3 signaling has been shown to
Figure 3. Deletion of Wwox results in defective mammary branching and lobuloalveolar development. (A–B) Representative
microphotographs obtained from whole mounts of 12 week virgin BK5 Wwox WT (A) and KO (B) mammary glands. The impaired branching
phenotype was also dramatically evident in mammary gland from MMTV KO mice as illustrated in (C), extreme case of branching impairment in a 24
week virgin MMTV Wwox KO mammary gland. (D) The average number of branches/mm of ductal length was quantified for BK5-Cre (2); Wwox
flox/flox
(Cre (2) WT, n=4), BK5-Cre (+); Wwox
+/+ (Cre (+) WT, n=4), and BK5-Cre (+); Wwox
flox/flox (Wwox KO, n=5). A small yet statistically insignificant
(p=0.06) decrease in branching can be seen in Cre(+) WT as compared to Cre(2) WT. The decreased branching found in Wwox KO mammary glands
was significant when compared to either Cre (2) WT (p=0.0002) or Cre (+) WT (p=0.018). (E) Quantification of branches/mm ductal length in 24
week virgin MMTV Wwox WT controls (MMTV-Cre (2); Wwox
flox/flox and MMTV-Cre (+); Wwox
+/+ were grouped together, n=4) and MMTV Wwox KO
(MMTV-Cre(+); Wwox
flox/flox, n=4) mammary glands. Branching was statistically significantly decreased in Wwox KO when compared to WT controls
(p=0.017). Error bars indicate standard deviation.
doi:10.1371/journal.pone.0036618.g003
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From our microarray analysis we identified significant up-
regulation of several genes related with the Jak/Stat3 signaling
pathway (see Table S1). For instance, IL6st, the coreceptor and
signal transducer of the pathway, was upregulated 4.17 fold
(p=0.005), Jak1 was upregulated 3.04 fold (p=0.003) and Stat3
was upregulated 2.4 fold (p=0.01). To determine whether Stat3
was activated (i.e. phosphorylated) we analyzed phospho-Stat3
expression by means of immunohistochemistry in mammary gland
samples from BK5 Wwox WT (n=3) and KO (n=3) mammary
glands. We found that Wwox KO mammary epithelium had a
significantly higher number of cells that were positive for strong
nuclear phospho-Stat3 staining (p,0.003) (Figures 6 A–C). We
also compared levels of phospho-Stat3 by means of Western
blotting in BK5-Cre WT and KO epithelial organoids at p18.5, we
indeed found a significant increase in phospho-Stat3 expression in
the KO samples (Figure 6D).
In the canonical Wnt pathway we found that several genes were
significantly upregulated in Wwox KO mammary epithelium. This
pathway was also highlighted by the GO analysis of the gene
expression data (Figure 4C). Gsk3b was increased 6.65 fold
(p=0.0044). In addition, we identified over-expression of the
Lrp6 coreceptor (1.8 fold; p=0.0004) and the signal transducer
Dishevelled (Dvl1) (1.8 fold; p=0.0033) at a less stringent statistical
cutoff (under 2 fold changes). The b-catenin gene was upregulated
3.85 fold (p=0.0007) in our microarray. To determine whether
the noted upregulation of b-catenin mRNA and other canonical
pathway components resulted in an increase of nuclear localized
b-catenin protein we performed immunohistochemical analysis on
mammary gland sections from 12 week old virgin BK5-Cre mice.
We found that all protein was localized to cytoplasm and cell
membrane, no nuclear localization was noted and no differences
were observed between BK5 WT and KO mammary samples,
indicating that likely most b-catenin is degraded in the cytoplasmic
compartment and does not translate in hyperactivation of said
pathway. This is consistent with the findings that no classical target
genes of the canonical Wnt pathway were observed upregulated in
KO mammary glands (e.g. Cyclin D1, Myc, Fgf20) and no change in
proliferation was observed.
Discussion
Previous mouse Wwox KO models have shown that deletion of
this gene dramatically affects the lifespan of the animal, all mice
die by 3–4 weeks of age thus making observations in adult tissues
impossible [18,19]. Here we present the first report on the effects
of conditional Wwox deletion in developing and mature mouse
mammary epithelium.
Figure 4. Wwox-KO BK5-Cre transgenic mice model gene expression profile study. (A) Heatmap of the differentially expressed genes
between Wwox WT vs. Wwox KO mammary gland epithelial organoid samples (p,0.01; 2 Fold changes). Color scale at bottom of picture is used to
represent expression level: low expression is represented by green, and high expression is represented by red. (B) Expression graph of the 913
deregulated probes (136 probes down-modulated and 777 up-modulated) among Wwox WT and Wwox KO mammary epithelial organoid samples.
(C) Scatterplot graph showing the representative clusters, after redundancy reduction of the statistical significant GO terms (p,0.025) enriched in the
deregulated gene list, in a two dimensional space related to GO terms’ semantic similarities. Bubble color indicates the p-value of GO terms
(expressed as Log10 p-value) and bubble size indicates the frequency of the GO term in the underlying GOA database (bubbles of more general
terms are larger).
doi:10.1371/journal.pone.0036618.g004
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deleting Wwox in the mammary gland leads to tumor formation.
Importantly, we found no evidence of tumor formation in the
mammary gland or any other tissue by either of the two
conditional KO approaches utilized, even if these mice were
monitored up to 1.4 years of age. This strongly suggests that Wwox
does not behave as a classical highly penetrant tumor suppressor
gene in mammary gland epithelium as previously thought [4]. Our
studies clearly indicate that loss of Wwox expression is not sufficient
for tumor formation. Furthermore, our findings are in clear
disagreement with previous speculation suggesting that Wwox
haploinsufficiency is tumorigenic [18,29,30,31]. Importantly,
Wwox ablation did not lead to the development of hyperplasia or
preneoplastic lesions and no increase in cell proliferation was
observed in mammary gland epithelium. This suggests that Wwox
loss of expression is perhaps of more relevance during the
progression stages of tumorigenesis rather than in the initiation of
neoplasia. In fact, we did find that loss of Wwox in the mammary
gland is associated with an increase in the expression of several
genes associated with tumor progression.
Inprevious studies,Abdeenet alreportedincreasedsusceptibility
to mammary carcinogenesis in Wwox+/2mice that were back-
crossed onto the mammary tumor-susceptible C3H genetic
background. Thus, an effect of Wwox in tumor initiation cannot
be ruled out at this point. There is also a possibility that genetic
backgroundmayplayaroleinmaskingsomemammaryphenotypic
effects of Wwox ablation since our studies were performed in a
mixed129SV/C57Bl/6geneticbackground.However,itisunlikely
that we would not see any signs of mammary cancer predisposition
as described throughout this report.
We further observed that Wwox ablation results in a significant
impairment in mammary gland ductal branching in virgin mice.
Perhaps the lack of Wwox expression affects the ability of epithelial
cells to invade the mammary fat pad during development.
Furthermore several genes associated with tissue remodeling and
extracellular matrix interactions were observed deregulated. For
instance, Timp2 and Timp3 were both found significantly
upregulated in Wwox KO epithelium (Table S1).
However, the observed defects in mammary gland morpho-
genesis did not inhibit normal functional differentiation since both
BK5 and MMTV Wwox KO mice are able to produce mature
mammary epithelial gland structures during pregnancy leading to
milk production and normal lactation.
In our gene expression studies we found that the Wnt5a gene is
significantly upregulated in Wwox-ablated mammary epithelium.
The Wnt5a ligand primarily signals through the planar cell polarity
pathway but has the potential to activate the canonical Wnt
signalingpathwayaswelldependingonwhichsetofcoreceptorspair
with the Frizzled receptor upon Wnt5a binding [32]. High levels of
Wnt5a expression have been associated with osteosarcoma [33],
prostate carcinoma [34] and metastatic melanoma [35]. Interest-
ingly in normal tissue such as the developing mammary gland high
levels of Wnt5a are associated with decreased cell proliferation and
delayeddevelopment[36].Furthermore,Wnt5aover-expressionhas
been shown to lead to developing a very similar phenotype to what
we observed in Wwox KO mammary epithelium. Wnt5a overexpres-
sioninhibitsductalextensionandlateralbranchingwhileWnt5a
2/2
mammary tissue exhibits an accelerated developmental capacity
compared with wild-type tissue [36].
Anumberofdifferentcellsignalingpathwayshavebeenshownto
activate transcription of the Wnt5a gene such as TGFb, TNFa,
Hedgehog, and IL-6/Jak/Stat3 (reviewed in [37]). We chose to
focus on the Jak/Stat3 pathway not only because of its association
with Wnt5a expression but also because several transcripts of said
pathway were detected upregulated in Wwox KO mammary
epithelium.
Mammalian Wnt5a is known to be a Stat3-target gene due to
tandem Stat-binding sites found in a region of intron 4 of the gene
[27]. In the mouse mammary gland, activation of the transcription
factor Stat3 by tyrosine phosphorylation has primarily been
associated with inducing the transcription of genes involved in the
initiation of cell death and tissue remodeling during mammary
gland involution post lactation [38]. Previous analyses for
phospho-Stat3 have shown that Stat3 is weakly activated in virgin
mammary gland, turned off at the onset of pregnancy and
reactivated for a short time at the end of pregnancy and the
beginning of lactation. Stat3 signaling appears to remain silent for
the duration of lactation until it is strongly reactivated at the
beginning of involution [39]. In our studies we observed that
phospho-Stat3 levels are significantly increased in Wwox KO
mammary epithelium from virgin and pregnant mice (P18.5).
Taking its role in involution into account we would expect to
observe increased apoptosis due to the increased activated Stat3
but we saw no significant difference in cell death between WT and
Wwox KO mammary glands (data not shown). In regards to
tumorigenesis, despite having a pro-apoptotic function in mam-
Figure 5. Wnt5a expression increases in BK5 Wwox KO mammary epithelium. Semi-quantitative RT-PCR was performed on cDNA synthesized
from RNA obtained from mammary epithelial organoids (3 different animals per group) as discussed in Materials and Methods. Lanes from left to
right are: (lanes 1–3) 8 week virgin Wwox WT, (lanes 4–6) P18.5 Wwox WT, (lanes 7–9) 8 week virgin Wwox KO, and (lanes 10–12) P18.5 Wwox KO.
Wwox expression is shown in the middle panel as further verification of Wwox ablation. Gapdh expression is shown as a normalization control. Each
PCR reaction was performed at 24, 26, 28 and 32 cycles to ensure that reaction was in linear range. Results shown at 24 cycles.
doi:10.1371/journal.pone.0036618.g005
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active in breast cancers at low levels and these cancers appear to
become addicted to Stat3 [39]. Further studies will be required to
better understand the interplay between loss of WWOX function
and Stat3 activation.
We also observed that the expression of several components of
the canonical Wnt pathway were upregulated in Wwox KO
mammary epithelium. Inhibition of WWOX has previously been
associated with increased signaling through this pathway as shown
by stabilization of the b-catenin protein as well as increased
transcriptional activity in cell lines. It was shown that WWOX
binds Dvl-2 and it was proposed that WWOX could play a role in
sequestering such signal transducer in the cytoplasmic compart-
ment [40]. Even though we observed an increase in the expression
of b-catenin at gene expression level, we did not detect active b-
catenin nuclear translocation nor did we observe an increase in the
expression of known transcriptional target genes such as Cyclin D1,
Myc or Fgf20 or increase in cell proliferation. Further experiments
will be needed to clarify the effect of Wwox ablation on the
canonical Wnt signaling pathway.
In summary, we report the first characterization of tissue
specific targeted ablation of the putative tumor suppressor gene
Wwox in adult mouse tissues. We demonstrated that conditional
deletion of Wwox in the mouse mammary gland does not result in
tumorigenicity. The fact that WWOX expression is lost in multiple
neoplasias by a variety of mechanisms is undeniable and very well
documented [4,5,7,41]. Thus, our data indicate that WWOX does
not behave as a classical highly penetrant tumor suppressor gene
and more likely the loss of WWOX expression is related to tumor
progression. Experiments are in progress to determine whether
Wwox ablation plays a role in mammary gland tumor progression.
Materials and Methods
Ethics statement
Mice used in these studies were maintained in a clean, modified-
barrier animal facility, fed regular commercial mouse diet (Harlan
Lab, Indianapolis, IN) under controlled light (12L:12D) and
temperature (68–74uF). All animal research was conducted in
facilities accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care International at the
University of Texas, M.D. Anderson Cancer Center, Science Park,
following international guidelines and all research was specifically
approved by the University of Texas M. D. Anderson Cancer
Center Institutional Animal Care and Use Committee, (Animal
Welfare Assurance Number A3343-01).
Generation of conditional Wwox knockout mice using
BK5-Cre and MMTV-Cre mediated deletion
Female Wwox
flox/flox mice (129SV/C57Bl/6 background) were
bred with male mice homozygous for the Cre recombinase gene
under control of either the bovine keratin 5 (BK5) promoter or the
MMTV promoter (Line D, [25]) to generate the Wwox
+/DCre F1
generation. Generation of Wwox
flox/flox mice is discussed elsewhere
[19]. BK5-Cre transgenic mice (129SV/C57Bl/6 background) were
obtained from the laboratory of Dr. David Johnson (MDACC,
Science Park) while the MMTV-Cre transgenic mice (129SV/
C57Bl/6 background) were obtained from Jackson Labs (stock
#003553) Genotypes were determined by PCR using the oligonu-
cleotide primers: Cre F: 59-GCCTGCATTACCGGTCGATG-
CAACG-39 Cre R: 59-GTGGCAGATGGCGCGGCAACAC-
CAT-39 Wwox-N1: 59-ATGGGCCGAAACTGGAGCTCAGA-
A-39 Wwox-N2: 59-TCAGCAACTCACTCTGGCTTCAAC-39
Wwox-L: 59-GCATACATTATACGAAGTTATTCGAG-39.
Figure 6. Wwox deletion correlates with increased phospho-Stat3 protein in mammary epithelium. (A–B) Immunostaining for phospho-
Stat3 (pStat3) protein in histological sections from 12 week virgin BK5 Wwox WT (A) and Wwox KO (B) mammary glands. Strong nuclear staining can
be seen in the majority of cells in Wwox KO sections. (C) Quantification of percentage of cells positive for pStat3 staining in Wwox WT (n=3) and
Wwox KO (n=3) histological sections. A total of 1000 cells were counted from random fields within each sample. (D) Whole cell lysates from
mammary epithelial organoids from P18.5 BK5 Wwox WT (n=3; WT4, WT5, WT6) and Wwox KO (n=3; KO4, KO5, KO6) mice, were probed pStat3 levels.
Wwox protein levels are shown to verify Wwox knockdown. Total Stat3 levels are shown as a control and Actin protein levels are shown as a loading
control.
doi:10.1371/journal.pone.0036618.g006
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and morphometric analysis
For whole mounts, the 4
th inguinal mammary glands were
dissected, spread onto glass slides and fixed with formalin overnight
and stained with carmine alum by standard procedures. Mammary
gland whole mount slides were then scanned for image analysis and
morphometry using the ScanScope CS system (Aperio Technolo-
gies, Inc., Vista, CA) and scans were analyzed for morphometric
features such as number of branches per mm of ductal length.
Immunohistochemistry
For immunohistochemistry, formalin-fixed paraffin sections
from mammary glands were deparaffinized and tissue sections
were treated with 10 mM Citrate buffer (pH 6.0; 15 min,
microwave) for antigen unmasking and Biocare blocking reagent
(Biocare) for blocking endogenous immunoglobulin in cases using
primary antibodies. Staining was then performed using DAB
(Dako) according to manufacturer’s instructions. Primary antibod-
ies used were rabbit anti-Wwox [14] (1:50 dilution), rabbit anti-
pSTAT3 (Cell Signaling Technology, 1:50 dilution), rabbit anti-
Estrogen Receptor alpha (Santa Cruz, 1:500 dilution), mouse anti-
Progesterone Receptor (Abcam, 1:100 dilution) and rabbit anti-
Ki67 (Bethyl, 1:250 dilution). Tissue sections were counterstained
with hematoxylin. Quantification of cells that were positive for
pSTAT3, ERa, PR or Ki67 was performed by scanning each
stained section with the ScanScope system as described above. A
thousand epithelial cells from random fields within the tissue
section were counted to determine the percentage of cells that
were positive for the respective staining.
Mammary gland transplantation experiments
Twelve week old virgin BK5-Cre Wwox KO mice served as
mammary epithelium donors. Mammary tissues were minced into
small pieces (,1m m
3) and were used for transplantation into
recipient mice. Recipient mice (n=10) were 4 week old female
SCID mice whose left and right 4
th mammary fat pads (MFPs) had
been cleared as previously described [42]. The sites of the left
MFPs were inoculated with mammary epithelial cells harvested
from BK5-Cre Wwox-KO mice. Recipient mice were monitored for
10 months and transplanted MFPs were dissected. Analysis of
MFPs was done by whole mount and histological examinations.
Microarray data processing, statistical and data mining
analyses
Mammary gland epithelial organoids were obtained as previ-
ously described [43] from three WWOX-KO mice (BK5-cre+;
WWOX
flox/flox) and from three WWOX-WT mice (BK5-cre -;
WWOX
flox/flox). Total RNA was isolated and purified using the
TRIzol/RNeasy Kit (Qiagen) from each mammary gland sample.
RNA concentration and integrity were measured on an Agilent
Bioanalyzer RNA 6000 Nanochip (Agilent Technologies). Five
micrograms of total RNA per sample were used for cDNA
synthesis, labeling and hybridization to whole genome Affymetrix
GeneChip Mouse Genome 430 2.0 Arrays. Labeling and
hybridization to Affymetrix GeneChips was carried out at the
Genomics Core Facility at the MDACC. Briefly, we carried out
QC and normalization procedures in R/Bioconductor [44] using
the simpleaffy package [45].
To identify differentially expressed genes between the WWOX-
WT vs. WWOX-KO mammary gland organoid expression
profiles, we utilized the modified two-sample t-test using Limma
package [46]. Raw datasets have been submitted to NCBI GEO
database with accession number: GSE36665. Heatmap visualiza-
tion of differentially expressed transcripts were done with the
MultiExperiment Viewer software (MeV 4.8) [47]. For automated
functional annotation and gene enrichment analysis, we used the
Database for Annotation, Visualization and Integrated Discovery
(DAVID) [48]. The DAVID resource calculates over-representa-
tion of specific biological themes/pathways with respect to the
total number of genes assayed and annotated. REViGO resource
was employed to summarize and visualize the enriched GO terms
in a scatterplot graph based on the p-values obtained by DAVID.
This allows the identification of biological themes/pathways
within a specific list of differentially expressed genes.
RNA isolation and real time and semi-quantitative RT-PCR
Total RNA was isolated from mammary epithelial organoids
from Wwox WT and KO female mice (n=3 different mice in each
group) using Trizol (Life Technologies) extraction and then
cleaned up with Qiagen RNeasy Mini Kit; 300 ng of total RNA
was used for reverse transcription using the High Capacity cDNA
Reverse Transcription kit (Applied Biosystems). One uL of the
20 uL reverse transcription reaction was used for real-time PCR
ran on the 7900HT real-time PCR system (Applied Biosystems).
Taqman Gene Expression Assays (Applied Biosystems) for mouse
Wwox (assay ID: Mm01247380_m1) and 18S rRNA (assay ID:
Hs99999901_s1) were used in separate reactions to determine
Wwox expression relative to 18S expression in each sample.
Experiments were performed in triplicate. Wwox expression was
normalized first to 18S expression within each sample and then to
WT levels. For semi-quantitative RT-PCR 1 uL of cDNA reaction
was added to a PCR reaction using the GoTaq Green Master Mix
(Promega). Forward and reverse primers for mouse Wnt5a, Wwox
and Gapdh were added to final concentration of 2 pg/uL and are
as follows: Wnt5a F5 9-TCCTTCGCCCAGGTTGTTAT-39,
Wnt5a R5 9-GCAGAGAGGCTGTGCACCTA-39, Wwox F5 9-
TGGAGCAAATTCGGGAATAG-39, Wwox R5 9-ATTGCTTC-
CACCTTGGCTTT-39, Gapdh F5 9-CGTCCCGTAGA-
CAAAATGGT-39, Gapdh R5 9-TCAATGAAGGGGTCGTT-
GAT-39. Reactions were run on a BioRad iCycler under
standard conditions for 24, 28 and 32 cycles to ensure that
reaction conditions were in linear range. PCR reaction products
were electrophoresed on 2% agarose gel, stained with GelRed
Nucleic Acid Stain (Phenix) and visualized under UV.
Western blot analysis
To monitor endogenous activation of the Stat pathway in
mammary epithelium total protein extracts were prepared from
the 4
th inguinal mammary epithelial organoids. Protein isolation
was done using RIPA buffer (50 mM Tris buffer pH 7.5, 150 mM
NaCl, 0.25% sodium deoxycholate, 10 mM EDTA, 1% NP40)
with protease inhibitor cocktail (Roche, Mannheim, Germany)
and the phosphatase inhibitors sodium vanadate (2 mM) and
sodium fluoride (5 mM). For western blotting, 20 ug of total
protein was separated on 12.5% SDS-PAGE and transferred to a
PVDF membrane. Membranes were blocked and antibodies were
diluted in 5% dry milk/TBST. Primary antibodies used were:
rabbit anti-Wwox (1:2000) [7], rabbit anti-phospho-Stat3 (Santa
Cruz, 1:1000) and mouse anti-Stat3 (Santa Cruz, 1:1000). HRP
conjugated secondary antibodies were used followed by chemilu-
minescence autoradiography. Actin was used as the protein
loading control and it was detected using monoclonal anti-actin
antibody (Sigma, 1:1000) and HRP conjugated anti-mouse
secondary antibody (1:5000). Immunodetection was performed
using ECL Western Blotting Detection Reagents (GE Healthcare)
as described by the manufacturer.
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Figure S1 Conditional BK5 Wwox KO mice die prema-
turely; Kaplan-Meier survival curve of mice with BK5-
Cre mediated Wwox ablation.
(DOCX)
Figure S2 Cytokeratin 5 immunostaining in BK5 KO
mammary gland (10 wk old virgin mouse). As can be
observed, K5 staining is limited to the basal layer of every
epithelial structure as in normal wild type mammary gland. No
obvious abnormalities in epithelial differentiation were detected.
(DOCX)
Table S1 List of 913 probes from Affymetrix gene expression
profile differentially expressed between Wwox KO and Wwox WT
mammary gland epithelium (p,0.01; 2 fold changes).
(XLS)
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